There's a couple of key changes happening in the consumer facing FMCG brands which I think investors need to taje notice of and think about. Investors of #itc#hul#britannia need to think carefully about this. 👇👇
1️⃣ The retailer is becoming ecommerce heavy. Ex: I buy all my grocery on Tata big basket or Amazon. To me this represents a change in power dynamics across the value chain. The ability of Amazon or big basket to bargain is far higher than an offline only limited space distributor
Or a mom and pop front end kirana store. Now how fast this shows up in numbers and depresses working capital for brands is a function of market share of e-retail vs that of offline retail. I'd definitely track this if I were invested in the consumer facing brands.
2️⃣ traditional retailers have limited consumer facing shelf space which is generally at premium real estate locations. This means that there is a clear advantage to the retailer to only keeping top K brands. eCommerce is changing that.
Companies like Amazon and flipkart are changing that notion because the consumer facing real estate is practically infinite. It's an app. This means that private equity funded direct to consumer brands that want to give larger chunk of profits to retailer can do so.
As an anecdote of the rise of new brands:
For many years tops, mother's recipe and similar brands had a practical monopoly over pickles. These days im seeing a lit more new brands on big basket like organic nation, indi-secrets etc and as a pickle connoisseur I can vouch that..
The newer brands offer a differentiated product that I personally prefer.
Tops and mothers recipe are ready to be disrupted. So are your favorite brands, unless they have a force of nature behind them (eg: tata brands on big basket).
Worth thinking about and keeping in mind.
• • •
Missing some Tweet in this thread? You can try to
force a refresh
I studied #camlin#fine#sciences for past few weeks. Does not deserve full thread imo so only sharing some key take-aways.
👇👇👇
few things i like:
lot of triggers: more efficient manufacturing (lot of capex in Dahej), plans to forward integrate all catechol and hydroquinone production (higher Gross margins).
Manufacturing becoming more efficient incrementally(dahej instead of italy and other geopgraphies), the battery play (Lockheed contract) which definitely can be huge. Fermentation company that they are aquiring for omega 3 fatty acids production
Let us estimate the ROIIC for #Pix transmissions. See screener.in page for details on the capex that is ongoing.
To be more precise, ill estimate the ROCE for incremental capital deployed
1. 60 cr capex happening. 50% capacity expansion. 2. EBIT of 96cr in FY21. So incremental EBIT of 48cr assuming no margin expansion. 3. 150cr Working capital for FY21. 75cr for incremental sales assuming no change in WC position. 4. 48/(60+75) = 35.5%
FY21 ROCE is 28%.
Time for a thread on things I have learned in last 1 year. My key takeaways, and also mistakes I made.
If you like the thread, please retweet this tweet so it can benefit maximum investors.
🧵🧵🧵👇👇👇
1⃣ Predicting nifty levels and what broader markets will do is an exercise in futility
Nobody can do it consistently. This is because there are too many random variables (probabilistic outcomes) which control the level of nifty including but not limited to:
investors ease of access to money, federal bank action across the world, profitability of cos, demand, supply, extent of formalisation of economies, expectations of aforementioned factors and very broadly, the extent of innovation coming into the market
"Upsurge in the valuation of API companies is also because of formulation companies stocking up APIs. (~ to defensive buying of semiconductors by consumer electronics companies) “If earlier they’d stock for 3m , they began stocking for 6m-12m"
Correct comparison is to nearby countries with similar per capita incomes. India standa out head and shoulders above everybody else. Don't compare to China Japan uk and usa or russia. I am hopeful about the future.
Q1FY22 concall was today for 🌋🌋. My key takeaways 👇👇
1⃣ Revenue & margin 🔻
In b/w lines:
Multiple factors for affecting both. Unit 3 has been commercialised, but not ramped up. Operating de-leverage at play. CMS revenue lumpy. As biz mix changes, so do margins.
Some CMS revenue postponed due to complex nature of projects (more on that later).
2⃣ Medium term guidance of 15-20% topline growth and 20% EBITDA margins
In b/w lines:
What we need to understand is that this is a very lumpy biz, even YoY there wont always be 15% growth.
Prices for Generic APIs are as per market movements. CMS revenues are lumpy. How can a management predict when will the Patent protected innovator molecule get commercialised? They simply cannot. With unit 3 ramping up & CMS revenue coming up, i fully expect 20% EBITDA margins